Effect of Molecular Hydrogen in Patients With Non Alcoholic Faty Liver Disease
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Changes in blood parameters Coenzyme Q 10 in plasma
研究概览
简要总结
Molecular hydrogen H2 acts as antioxidant which selectively reduces cytotoxic harmful reactive oxygen species ROS and concomitantly acts as biological messenger, which mediates several signaling pathways that play cytoprotective role in many human diseases. Due to their small size and high permeability, H2 is easily transportable into subcellular structures as mitochondria.
详细描述
Non-alcoholic fatty liver disease, NAFLD, is the most common cause of liver disease. According to the forecasts, the non-alcoholic steatohepatitis will be the most common cause of liver transplantation and hepatic mortality in 2030. NAFLD is also a significant risk factor for the development of hepatocellular carcinoma, even in the non-cirrhotic stage of liver disease. The prevention of the progression of NAFLD to NASH (nonalcoholic steatohepatitis) is therefore a key factor in preventing this unfavorable prognosis.
Obesity and its associated comorbidities are among the most widespread and challenging conditions in the confrontation of the medical profession in the 21st century. The main metabolic consequence of obesity is insulin resistance, which is strongly associated with the storage of triacylglycerols in the liver. Hepatic steatosis may be associated with steatohepatitis, a condition that can lead to liver cirrhosis and, in the final stage, liver transplantation.
According to various sources, the incidence of NAFLD in the population is 20-30%, in obese up to 60%, which makes it the most common liver disease. In the USA, it is even 3 times more common than type 2 diabetes mellitus and 5-10 times more common than chronic hepatitis C. The incidence of non-alcoholic steatohepatitis NASH is 2-3% and is now thought to be the cause of up to 80% cryptogenic liver cirrhosis. The risk of developing cirrhosis in patients with simple hepatic steatosis is 1-2% over 8 years.
Insulin resistance, which is defined as an elevated HOMA (homeostasis model assessment) index above 1,4, is found in 70% of patients with NAFLD and plays a major role in the accumulation of triacylglycerols TAG (triacylglyceride) in the liver. Through the rise of hormone-sensitive lipase, hyperinsulinemia leads to the hydrolysis of free fatty acids FFA from visceral adipocytes to the portal vein, through which they enter directly into the liver, where they are esterified to TAG. Reducing the production of apolipoprotein B-100, which is an important part of their secretion from the liver into the circulation in the form of VLDL-lipoproteins, is also a potentiating factor in TAG deposition in the liver. Free oxygen radicals ROS (reactive oxygen species), which are formed due to the oxidative stress, are formed directly in the hepatocyte. However, their formation in visceral adipocytes has also been shown to be involved in liver damage. The main site of ROS are mitochondria. In NAFLD, known mitochondrial dysfunction leads to pathological oxidation of FFA (free fatty acid) in peroxisomes and microsomes, making them another source of ROS. ROS, through damage of the mitochondrial membrane by lipoperoxidation and induction of Fas-ligand expression on the hepatocyte, leads to cell apoptosis.
By activating stellate cells, a larger amount of extracellular matrix is formed - Mallory's hyaline, which is associated with the formation of balloon degeneration of hepatocytes, that is a typical histological feature of NASH.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 33 Years 至 69 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •People with age 33-69 years
- •Confirmation of fatty liver by ultrasonographic examination
- •Signed informed consent
- •Alcohol intake according to the AUDIT questionnaire 5 or less points for men or 4 or less points for women
排除标准
- •Unsigned informed consent
- •BMI < 25
- •Presence of severe inflammatory disease with activity (Crohn's disease, ulcerative colitis, active tuberculosis, rheumatoid arthritis, etc.)
- •Presence of acute infectious disease (acute hepatitis, peritonitis, cholecystitis, pancreatitis, etc.)
- •Presence of active neoplastic disease
- •Alcohol intake according to the AUDIT questionnaire more as 5 points for men or more as 4 points for women
研究组 & 干预措施
probands in the control group
13 probands in the control group who will receive placebo.
干预措施: placebo (Dietary Supplement)
patients with NAFLD
17 patients will receive molecular hydrogen
干预措施: HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada (Dietary Supplement)
结局指标
主要结局
Changes in blood parameters Coenzyme Q 10 in plasma
时间窗: 8 weeks
Coenzyme Q 10 in plasma (μmol/L)
Changes in blood parameters Insulin
时间窗: 8 weeks
Insulin (mIU/L)
Changes in blood parameters Beta carotene
时间窗: 8 weeks
Beta carotene (μmol/L)
Changes in blood parameters Coenzyme Q 10 in platelets
时间窗: 8 weeks
Coenzyme Q 10 in platelets (pmol/10\^9 cells)
Changes in blood parameters ALT
时间窗: 8 weeks
ALT (alaninaminotransferase) ukat/L
Changes in blood parameters Glucose
时间窗: 8 weeks
Glucose (mmol/L)
Changes in blood parameters Cholinesterase
时间窗: 8 weeks
Cholinesterase (ukat/L)
Changes in blood parameters TBARS
时间窗: 8 weeks
TBARS (μmol/L)
Changes in blood parameters AST
时间窗: 8 weeks
AST (aspartataminotransferase) ukat/L
Changes in blood parameters GMT
时间窗: 8 weeks
GMT (gamaglutamyltransferase) ukat/L
Changes in blood parameters Cholesterol
时间窗: 8 weeks
Cholesterol (mmol/L)
Changes in blood parameters Triacylglycerol
时间窗: 8 weeks
Triacylglycerol (mmol/L)
Changes in blood parameters Hemoglobin
时间窗: 8 weeks
Hemoglobin (g/L)
Changes in blood parameters LDH
时间窗: 8 weeks
LDH (lactatdehydrogenase) (mU/mL)
Changes in blood parameters MMP-9
时间窗: 8 weeks
MMP-9 (matrix-metalloproteinase 9) (% of change)
Changes in blood parameters SOD
时间窗: 8 weeks
SOD (superoxiddismutase) (ng/mL)
Changes in blood parameters NFkB
时间窗: 8 weeks
NFkB (nuclear factor kappa B) (% of change)
Changes in blood parameters Alpha tocopherol
时间窗: 8 weeks
Alpha tocopherol (μmol/L)
Changes in body parameters: Weight in kilograms, height in meters, waist circumference in centimeters
时间窗: 8 weeks
The following parameters will be measured for each proband before (time 0) and after the study (time 8 weeks): a) weight and height will be combined to report BMI in kg/m\^2, waist circumference in cm.
Changes in blood parameters ALP
时间窗: 8 weeks
ALP (alkaline phosphatase) ukat/L
Changes in blood parameters Albumin
时间窗: 8 weeks
Albumin (g/L)
Changes in blood parameters Bilirubin
时间窗: 8 weeks
Bilirubin total (umol/L)
Changes in blood parameters HOMA index
时间窗: 8 weeks
HOMA index (calculation)
Changes in blood parameters Leucocytes
时间窗: 8 weeks
Leucocytes (x10\^9/L)
Changes in blood parameters MDA
时间窗: 8 weeks
MDA (malondialdehyde) (μmol/L)
Changes in blood parameters 8-OHdG
时间窗: 8 weeks
8-OHdG (8-hydroxy-2-deoxyguanosine) (ng/mL)
Changes in blood parameters TNF alfa
时间窗: 8 weeks
TNF alfa (tumor necrosis factor alpha) (% of change)
Changes in blood parameters HSP 60
时间窗: 8 weeks
HSP 60 (heat shock protein 60) (% of change)
Changes in blood parameters HSP 70
时间窗: 8 weeks
HSP 70 (heat shock protein 70) (% of change)
Changes in blood parameters Platelets
时间窗: 8 weeks
Platelets (x10\^9/L)
Changes in blood parameters MMP-2
时间窗: 8 weeks
MMP-2 (matrix metalloproteinase2) (% of change)
Changes in blood parameters Gama tocopherol
时间窗: 8 weeks
Gama tocopherol (μmol/L)
Changes in blood parameters Coenzyme Q 10 in whole blood
时间窗: 8 weeks
Coenzyme Q 10 in whole blood (μmol/L)
次要结局
未报告次要终点
